A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis.

[1]  P. Gallo,et al.  Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis , 2022, Journal of Neurology.

[2]  B. Baradaran,et al.  Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies , 2022, Frontiers in Immunology.

[3]  X. Montalban,et al.  Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis , 2021, Neurology.

[4]  M. Filippi,et al.  Anti-CD20 therapies for multiple sclerosis: current status and future perspectives , 2021, Journal of Neurology.

[5]  D. Arnold,et al.  Secondary Progressive Multiple Sclerosis , 2021, Neurology.

[6]  H. Weiner,et al.  The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis , 2021, Multiple sclerosis journal - experimental, translational and clinical.

[7]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[8]  X. Montalban,et al.  Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry , 2021, European journal of neurology.

[9]  A. Sempere,et al.  Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population , 2020, Annals of clinical and translational neurology.

[10]  D. Arnold,et al.  Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial , 2020, The Lancet Neurology.

[11]  X. Montalban,et al.  Role of B Cells in Multiple Sclerosis and Related Disorders , 2020, Annals of neurology.

[12]  M. Freedman,et al.  Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years , 2020, Multiple sclerosis journal - experimental, translational and clinical.

[13]  V. Shaygannejad,et al.  Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial , 2020, Acta neurologica Scandinavica.

[14]  T. Ziemssen,et al.  The Role of TH17 Cells in Multiple Sclerosis: Therapeutic Implications. , 2020, Autoimmunity reviews.

[15]  S. Frequin,et al.  Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis , 2020, Multiple sclerosis international.

[16]  J. Smolders,et al.  B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers , 2020, Frontiers in Immunology.

[17]  Tjalf Ziemssen,et al.  Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol , 2020, BMC Neurology.

[18]  J. Wolinsky,et al.  An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability , 2020, Multiple sclerosis journal - experimental, translational and clinical.

[19]  M. Sormani,et al.  Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience , 2019, Multiple sclerosis.

[20]  D. Centonze,et al.  Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial , 2019, The Lancet Neurology.

[21]  D. Reich,et al.  Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. , 2019, Multiple sclerosis and related disorders.

[22]  L. Kappos,et al.  Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. , 2019, Multiple sclerosis and related disorders.

[23]  S. von Felten,et al.  Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis , 2019, JAMA neurology.

[24]  H. Lassmann.  Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis , 2019, Front. Immunol..

[25]  X. Montalban,et al.  Multiple sclerosis: clinical aspects , 2018, Current opinion in neurology.

[26]  X. Montalban,et al.  Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial , 2018, Multiple sclerosis.

[27]  Radleigh G. Santos,et al.  Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis , 2018, Cell.

[28]  A. Bar-Or,et al.  Reassessing B cell contributions in multiple sclerosis , 2018, Nature Immunology.

[29]  M. Sospedra.  B cells in multiple sclerosis , 2018, Current opinion in neurology.

[30]  S. Gil-Perotín,et al.  Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study , 2018, Journal of Neurology.

[31]  G. Disanto,et al.  Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland , 2018, PloS one.

[32]  D. Arnold,et al.  Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension , 2018, The Lancet Neurology.

[33]  R. Zhong,et al.  Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients , 2018, Medicine.

[34]  Spyridon N Papageorgiou,et al.  Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. , 2018, Journal of clinical epidemiology.

[35]  X. Montalban,et al.  Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial , 2017, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  David H. Miller,et al.  Diagnosis of multiple sclerosis: progress and challenges , 2017, The Lancet.

[37]  Bernhard Hemmer,et al.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.

[38]  J. Correale,et al.  Progressive multiple sclerosis: from pathogenic mechanisms to treatment. , 2016, Brain : a journal of neurology.

[39]  F. Piehl,et al.  Rituximab versus fingolimod after natalizumab in multiple sclerosis patients , 2016, Annals of neurology.

[40]  T. Ziemssen,et al.  Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[41]  Dragan Maric,et al.  Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis , 2016, Annals of clinical and translational neurology.

[42]  H. Wiendl,et al.  Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond , 2015, International journal of molecular sciences.

[43]  H. Siebner,et al.  Natalizumab in progressive MS , 2014, Neurology.

[44]  R. D. Du Pasquier,et al.  Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis , 2014, CNS Drugs.

[45]  Kathleen F Villa,et al.  The cost burden of multiple sclerosis in the United States: a systematic review of the literature , 2013, Journal of medical economics.

[46]  C. Klein,et al.  Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties , 2013, mAbs.

[47]  P. Rieckmann,et al.  The natural history of secondary progressive multiple sclerosis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[48]  George C. Ebers,et al.  The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.

[49]  P. Calabresi,et al.  Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.

[50]  A. Chan,et al.  B cell immunobiology in disease: evolving concepts from the clinic. , 2006, Annual review of immunology.

[51]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[52]  S. Vukusic,et al.  Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.

[53]  Anna D Schaal.  Alemtuzumab (Campath 1-H). , 2005, Clinical Journal of Oncology Nursing.

[54]  David H. Miller,et al.  Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis , 2005, Multiple sclerosis.

[55]  J. Relton,et al.  LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex , 2004, Nature Neuroscience.

[56]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[57]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[58]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis. , 2000, Brain : a journal of neurology.

[59]  G. Barker,et al.  Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H , 1999, Neurology.

[60]  D. R. Anderson,et al.  Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. , 1997, Biochemical Society transactions.

[61]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[62]  A. Prange,et al.  Course and prognosis of chronic progressive multiple sclerosis: Results of an epidemiological study , 1988, Acta neurologica Scandinavica.

[63]  D. Reich,et al.  Multiple Sclerosis , 2018, The New England journal of medicine.

[64]  D. Cadavid,et al.  [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis]. , 2010, Revista de neurologia.